In an Exclusive Interview the CEO of Advanced Proteome Therapeutics (APC) Discusses the Company's Technology and R&D Strategy

VANCOUVER, BC--(Marketwired - January 29, 2015) - Advanced Proteome Therapeutics Corporation ("APC" or the "Company") (TSX VENTURE: APC) (FRANKFURT: 0E8) announces that APC was profiled in a BioTuesdays.com interview with Leonard Zehr. In the interview, encompassing a wide range of topics, the CEO, Dr. Allen Krantz, discussed the Company's unique approach to developing a potential anti-cancer therapeutic. Dr. Krantz alluded to advantages of the technology, which is designed to combine multiple anti-cancer therapies in a single agent. He pointed out that the agent is not only intended to directly target tumors, but to stimulate the immune system and, in combination with other immunotherapeutic agents, such as the very exciting checkpoint inhibitors, achieve greater overall response rates and durable responses in patients than are currently being observed in the clinic.

After describing APC's unique approach and the thrust of current efforts, Dr. Krantz commented on data released this past September and current milestones. The complete interview can be found in the January 27th, 2015 edition of BioTuesdays, at http://biotuesdays.com/2015/01/27/in-conversation-with-allen-krantz/

About APC

APC has been applying its Foundation Trinity^™ Technology to proteins targeted for the treatment of cancers. Advanced targeted therapies are designed to attack primarily cancer cells and are expected to dominate the anti-cancer therapeutics' market in the near future. The Company's goals are not only to employ therapy targeted for tumor cells, but also to deliver combination therapy in a single, pure therapeutic agent. To achieve this end, it has been the Company's intention to utilize a unique protein (and related systems), not only as a delivery vehicle to tumor cells, but also as a scaffold upon which to attach each anti-cancer entity to its own specific site on the protein surface -- both key to efficient manufacturing and product development. The protein vehicle has emerged as a potential immunotherapeutic as it is implicated in activating the immune system to attack and help clear tumor cells. Immunotherapy is perhaps the most powerful current approach to cancer, and one of great commercial interest to the pharmaceutical industry.

ON BEHALF OF THE BOARD
Alexander (Allen) Krantz
President and Chief Executive Officer

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release. The forward-looking statements contained in this news release involve risks and uncertainties, and are subject to change based on various important factors including timely development and acceptance of new products, gaining product approval, successful entry into new markets, changes in financing conditions, and changes in FDA regulations.